• Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow
  • Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership
  • AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care
  • QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II, designed to deliver significant throughput and workflow benefits in the U.S. and Europe

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new fully automated Sample to Insight workflow and a separate AI-enabled risk stratification tool for TB progression, building on growing adoption of Diasorin LIAISON detection systems and a new automation partnership with Inpeco.

These developments are intended to help higher-throughput labs scale testing as screening demand for latent TB continues to grow. QIAGEN estimates the global latent TB testing market at approximately 75 million tests annually, growing about 4% to 5% per year. Only about 40% of this market has converted from traditional skin tests to modern blood-based interferon-gamma release assay, or IGRA, testing.

Together, the fully automated workflow is intended to position QuantiFERON as a complete Sample to Insight ecosystem, combining full automation, seamless traceability, and data-driven insights built on the foundation of QIAGEN's more than 20 years of leadership in TB testing.

Planned for launch in late 2027, this new workflow is designed for customers using Diasorin LIAISON systems aiming to automate the complete latent TB testing process without routine manual operator intervention, from preanalytical tube handling and incubation with Inpeco to detection on LIAISON systems.

Through its partnership with Inpeco, a global leader in track-based laboratory automation, QIAGEN is advancing total laboratory automation for QuantiFERON IGRA testing. The collaboration brings two purpose-built innovations, a dedicated QuantiFERON aliquoting system and an intelligent incubation system, fully integrated into the track to enable a seamless end-to-end automated workflow.

Separately, QIAGEN is developing an AI-enabled QuantiFERON risk stratification tool designed to analyze quantitative QuantiFERON results from all laboratory workflows, with initial customer use also targeted for late 2027.

The Inpeco partnership comes as QIAGEN and Diasorin continue to see strong customer adoption of LIAISON QuantiFERON-TB Gold Plus II, the next generation of the world's leading IGRA blood test for TB infection detection supported by more than 2,700 published studies and more than 160 million tests performed worldwide since launch.

The new chemistry, launched in November 2025 in Europe and other countries accepting the CE mark and in February 2026 in the U.S., offers significantly faster efficiency and turnaround time. QIAGEN and Diasorin are advancing initiatives that are on track to quickly transition all LIAISON customers running QuantiFERON to the new chemistry.

By enabling full automation of the QuantiFERON IGRA workflow, laboratories can decouple volume growth from staffing requirements, reduce hands-on time by up to 80% and transition to continuous, real-time processing. These capabilities are expected to significantly improve turnaround time, operational efficiency and scalability for high-throughput laboratories and larger testing networks.